North America Epigenetics Market Size
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Historical Data Period | 2019 - 2022 |
CAGR | 20.00 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
North America Epigenetics Market Analysis
The North America Epigenetics Market is expected to register a 20% of CAGR growth during the forecast period. The key contributor to the market is the growing burden of cancer and increasing investments into research and development activities.
According to the American Cancer Society, in 2020, around 1.8 million new cases will be diagnosed in the United States and about 606,520 people are expected to die due to it. Epigenetics modifications can influence the cellular responses with respect to the apoptosis, cell proliferation and senescence.
Hence, epigenetics has a very crucial role in cancer treatment and thereby it is expected to boost the market growth over the forecast period.
North America Epigenetics Market Trends
This section covers the major market trends shaping the North America Epigenetics Market according to our research experts:
Cardiovascular Diseases are Expected to Show a Steady Growth in the North America Epigenetics Market
Cardiovascular diseases are expected to show steady growth in the market during the forecast period. Recent studies have shown that epigenetics has a very significant role in cardiovascular diseases. The information of epigenetics can help in determining the response of an individual towards the drug. In addition, it can also be developed to assess the risk determinants for cardiovascular diseases. Hence, it can be a diagnosis and prognosis of cardiovascular diseases. Heart diseases are one of the leading cause of death in the United States. As per the Centre for Disease Control and Prevention, one person dies in every 37 seconds in America due to cardiovascular disease.
Furthermore, the increasing investments into R&D are expected to impact positively on the market. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), 2018, around USD 79.6 billion were spent on the research and development activities. Thus, the aforementioned factors are expected to impact positively on the market in this segment.
North America Epigenetics Industry Overview
The key players in the North America Epigenetics market are Abcam PLC, Active Motiff, Diagenode Inc., F. Hoffmann-La Roche Ltd, Illumina Inc., Qiagen N.V., Merck & Co. Inc., ThermoFisher Scientific and Zyhmo Research Corporation.
North America Epigenetics Market Leaders
-
Diagenode Inc.
-
Merck KGaA
-
Illumina Inc.
-
Active Motiff
-
Abcam Plc
*Disclaimer: Major Players sorted in no particular order
North America Epigenetics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Burden of Cancer Diseases
- 4.2.2 Increasing Investments into Research and Development Activities
- 4.2.3 Rising Epigenetic Applications in Non-oncology Diseases
-
4.3 Market Restraints
- 4.3.1 Presence of Stringent Regulatory Framework
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Product
- 5.1.1 Instruments
- 5.1.2 Reagents & Kits
- 5.1.3 Others
-
5.2 By Applications
- 5.2.1 Oncology
- 5.2.2 Autoimmune Diseases
- 5.2.3 Metabollic Diseases
- 5.2.4 CNS/Pain Diseases
- 5.2.5 Cardiovascular Diseases
- 5.2.6 Others
-
5.3 By Technology
- 5.3.1 Methylation
- 5.3.2 Acetylation
- 5.3.3 Phosphorylation
- 5.3.4 Others
-
5.4 By Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abcam PLC
- 6.1.2 Active Motiff
- 6.1.3 Diagenode Inc.
- 6.1.4 F. Hoffmann-La Roche Ltd
- 6.1.5 Illumina Inc.
- 6.1.6 Qiagen N.V.
- 6.1.7 Merck KGaA
- 6.1.8 TherFisher Scientific
- 6.1.9 Zyhmo Research Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityNorth America Epigenetics Industry Segmentation
Epigenetics refers to the study of genetic controlling by factors except the DNA sequencing of an individual. It majorly deals with the gene expression. The North America Epigenetics Market is segmented By Product, By Application, By Technology and Geography.
By Product | Instruments | |
Reagents & Kits | ||
Others | ||
By Applications | Oncology | |
Autoimmune Diseases | ||
Metabollic Diseases | ||
CNS/Pain Diseases | ||
Cardiovascular Diseases | ||
Others | ||
By Technology | Methylation | |
Acetylation | ||
Phosphorylation | ||
Others | ||
By Geography | North America | United States |
Canada | ||
Mexico |
North America Epigenetics Market Research FAQs
What is the current North America Epigenetics Market size?
The North America Epigenetics Market is projected to register a CAGR of 20% during the forecast period (2024-2029)
Who are the key players in North America Epigenetics Market?
Diagenode Inc., Merck KGaA, Illumina Inc., Active Motiff and Abcam Plc are the major companies operating in the North America Epigenetics Market.
What years does this North America Epigenetics Market cover?
The report covers the North America Epigenetics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the North America Epigenetics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
North America Epigenetics Industry Report
Statistics for the 2024 North America Epigenetics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. North America Epigenetics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.